Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Alper H.YUKSEL who wrote (26557)	11/17/1998 4:19:00 AM
From: Cheryl Galt	Read Replies (1) \| Respond to of 32384

Alper and all, I can't guess the price of Panretin get, but I did price Allergan's new Tazorac gel - approved June 1997. TAZORAC (a receptor-selective retinoid) seems to be a current preferred topical treatment for mild/moderate psoriasis and severe acne. Tazorac (tazarotene) is not cheap. It comes in 0.05% and 0.1%. Bartell didn't carry the 0.05% gel. For the 0.1% gel 30g tube -- $079.79 100g tube - $246.29 ------------------------------- To limit side effects, the stuff must be put on carefully -- sparingly, and ONLY on the lesions. I assume Panretin gel would need the same precautions, spelled out in this NPF article: March 1998 - Tazorac Needs Attention to Detail Misuse or misunderstanding may lead to early termination of therapy psoriasis.org Reading the above article, I should think that if during trials patients apply the gel at home, their expertise -- or lack of it -- could greatly impact the test results. -------------------- General info from the National Psoriasis Foundation Website: psoriasis.org -------------------- BTW, for pregnant or nursing women, tazorac is Category X -- totally counter-indicated, because it can cause severe birth defects. Any informed speculation regarding how Panretin gel might compare to Tazorac, for psoriasis and acne? -------------------- Now I'd better hit the sack, if I'm to be up in time for a possible bargain basement special east coast time. Alper, what time is it in Turkey?

To: Alper H.YUKSEL who wrote (26557)	11/17/1998 8:39:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Bear Stearns came out with a reiterated BUY this morning, keeping the 4Q loss at $0.02 and next year's gain at $0.09. They expect Panretin sales next year to be $14 million and ONTAK sales to be $14.5 million. Panretin sales are expected to grow to the $40-$50 million per year range and ONTAK is projected to eventually produce $30 million in annual sales. The y expect an ex-US, ex-Europe marketing deal for Panretin and ONTAK to be announced soon, possibly this year.